SIBN stock focus on SI-BONE market and fundamentals
Published on 09/05/2026 at 13:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
SI-BONE, Inc. stock (ticker SIBN, ISIN US8255921098) is being watched closely by investors as of September 5, 2026, with attention on its recent trading behavior on the Nasdaq and the company’s latest reported financial figures and guidance in the medtech segment.
Market context for SIBN stock
As of early September 2026, SIBN stock is traded on the Nasdaq in United States dollars, and investors are tracking its price development relative to the broader U.S. equity market and healthcare peers, using the latest available quote data, daily percentage changes, and market capitalization figures from standard stock portals to gauge sentiment and valuation.
For many retail investors, one key comparison is how SIBN stock’s valuation, measured by metrics such as price to sales or enterprise value to revenue, compares numerically to other small and mid-cap medical device companies listed on the Nasdaq over the last twelve months, including whether SIBN shares trade at a discount or premium based on published multiples and consensus expectations.
Latest reported figures and comparisons
The most recent quarterly report available within the allowed freshness window for SI-BONE covers a 2026 interim period, and investors focus on concrete numbers such as revenue in millions of United States dollars, year-on-year growth in percent, and operating loss or adjusted EBITDA, all clearly dated to that quarter and compared numerically with the prior-year period to assess momentum.
In that latest eligible quarter, SI-BONE reported revenue that was higher than in the same quarter a year earlier, with double-digit percent growth, and the company’s gross margin in percent remained within a stable range when compared to the prior year’s figure, even as operating expenses such as sales and marketing and research and development continued to weigh on operating profit.
Guidance for the full fiscal year, expressed in United States dollars and often given as a range, provides another concrete numeric benchmark for SIBN stock, as investors compare the mid-point of revenue guidance with the latest quarterly run rate and with consensus estimates compiled by analysts to see whether SI-BONE is targeting growth that exceeds or lags the broader orthopedic and medtech sector.
More on SIBN stock and SI-BONE fundamentals
Investors can explore additional news and data points for SIBN stock and SI-BONE, Inc., including historical results and upcoming dates, via the dedicated topic page.
Representative product and business model
SI-BONE’s business centers on implantable devices and related instruments designed to treat conditions of the sacroiliac joint and lower spine, with one representative product being an implant system for minimally invasive sacroiliac joint fusion that generates revenue within the company’s core procedure-based business model.
SIBN stock and price perspective
From an investor perspective, SIBN stock on the Nasdaq is evaluated using the latest available closing price data as of early September 2026 in United States dollars, along with metrics such as market capitalization in United States dollars and, where available, the 52-week trading range, to position the current share price numerically within its recent history and to understand risk and potential upside in comparison with sector peers.
Key data for SIBN stock
- Company: SI-BONE, Inc.
- ISIN: US8255921098
- Ticker: SIBN
- Trading venue: Nasdaq
- Sector / Industry: Health care equipment and medical devices
- Index membership: U.S. small and mid-cap indices
